Literature DB >> 18825884

[Regional lymph nodes at a distance].

B B R Kroon1, C A Hoefnagel, R A Valdés Olmos, O E Nieweg.   

Abstract

In 3 patients, two men aged 22 years and 38 years with melanoma, and one woman aged 46 years with breast cancer, local tumour growth recurred following regional lymph node dissection. All three developed metastasis in new distant regional basins, which were once more dissected. The first melanoma patient died from haematogenous metastasis, 2 years after the excision of his primary melanoma. The other melanoma patient was alive, without evidence of disease, 8 years after the treatment of his primary tumour. The breast cancer patient, who underwent contralateral axillary lymph node dissection, was also alive, without evidence of disease, 27 years after the treatment of her primary tumour. Diversion of lymphatic flow as a result of regional lymph node dissection for cancer may lead to metastasis to a distant lymph node basin if tumour growth recurs in the original area. Knowledge of this usually unknown phenomenon is important since metastasis to these new regional basins can still be treated curatively, in the form of another lymph node dissection. These distant lymph node basins must therefore be carefully checked during follow-up monitoring.

Entities:  

Mesh:

Year:  2008        PMID: 18825884

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Contralateral axillary lymph node metastasis and molecular changes in second primary breast cancer: a case report.

Authors:  Shuo Li; Fei Xie; Yan Li; Jue Wang; Rui Chen; Qian-Nan Zhu; Xiao-Ming Zha
Journal:  Gland Surg       Date:  2021-04

2.  Contralateral Axillary Lymph Node Metastases from Breast Carcinoma: Is it Time to Review TNM Cancer Staging?

Authors:  Francesca Magnoni; M Colleoni; D Mattar; G Corso; V Bagnardi; S Frassoni; G Santomauro; B A Jereczek-Fossa; P Veronesi; V Galimberti; V Sacchini; M Intra
Journal:  Ann Surg Oncol       Date:  2020-05-21       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.